448.91
price up icon1.40%   6.18
pre-market  시장 영업 전:  449.90   0.99   +0.22%
loading
전일 마감가:
$442.73
열려 있는:
$440.66
하루 거래량:
713.17K
Relative Volume:
0.69
시가총액:
$58.84B
수익:
$2.46B
순이익/손실:
$-319.09M
주가수익비율:
-181.74
EPS:
-2.47
순현금흐름:
$-52.09M
1주 성능:
+2.27%
1개월 성능:
+44.29%
6개월 성능:
+75.05%
1년 성능:
+70.88%
1일 변동 폭
Value
$438.21
$449.52
1주일 범위
Value
$421.81
$449.52
52주 변동 폭
Value
$205.87
$449.52

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
명칭
Alnylam Pharmaceuticals Inc
Name
전화
(617) 551-8200
Name
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
직원
2,230
Name
트위터
@alnylam
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
ALNY's Discussions on Twitter

ALNY을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
448.91 58.03B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
392.79 100.07B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
580.41 59.99B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
653.83 39.93B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
321.36 36.82B 3.81B -644.79M -669.77M -6.24

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-08-04 업그레이드 Oppenheimer Perform → Outperform
2025-08-04 업그레이드 Wolfe Research Underperform → Peer Perform
2025-07-30 재개 Raymond James Outperform
2025-07-21 개시 Truist Buy
2025-03-31 개시 Redburn Atlantic Buy
2025-03-24 업그레이드 JP Morgan Neutral → Overweight
2024-11-12 다운그레이드 Wolfe Research Peer Perform → Underperform
2024-10-16 개시 Scotiabank Sector Outperform
2024-08-16 업그레이드 Goldman Neutral → Buy
2024-02-16 다운그레이드 Goldman Buy → Neutral
2024-02-15 개시 Wolfe Research Peer Perform
2023-12-08 개시 Wells Fargo Equal Weight
2023-10-11 다운그레이드 Oppenheimer Outperform → Perform
2023-09-29 개시 Raymond James Outperform
2023-05-05 업그레이드 BMO Capital Markets Market Perform → Outperform
2023-04-26 개시 SMBC Nikko Neutral
2023-03-21 개시 Bernstein Outperform
2023-01-18 개시 Canaccord Genuity Buy
2022-09-09 재개 Morgan Stanley Equal-Weight
2022-07-13 개시 Cantor Fitzgerald Neutral
2022-06-27 다운그레이드 Guggenheim Buy → Neutral
2022-06-07 개시 William Blair Outperform
2022-04-25 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2022-03-01 개시 Citigroup Buy
2022-02-03 업그레이드 Guggenheim Neutral → Buy
2022-01-03 업그레이드 Piper Sandler Neutral → Overweight
2021-11-22 업그레이드 Goldman Neutral → Buy
2021-11-22 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2021-11-01 업그레이드 Oppenheimer Perform → Outperform
2021-10-04 업그레이드 UBS Neutral → Buy
2021-08-04 다운그레이드 Piper Sandler Overweight → Neutral
2021-02-22 다운그레이드 Guggenheim Buy → Neutral
2021-02-12 다운그레이드 Citigroup Buy → Neutral
2021-02-12 재확인 H.C. Wainwright Buy
2021-01-25 다운그레이드 BMO Capital Markets Outperform → Market Perform
2020-09-30 재개 Berenberg Hold
2020-09-08 개시 Citigroup Buy
2020-08-11 다운그레이드 Oppenheimer Outperform → Perform
2020-05-13 개시 RBC Capital Mkts Sector Perform
2020-05-07 다운그레이드 JP Morgan Overweight → Neutral
2020-04-24 재개 Evercore ISI Outperform
2020-03-19 개시 Berenberg Buy
2019-12-19 재확인 Chardan Capital Markets Buy
2019-11-20 개시 Oppenheimer Outperform
2019-11-13 개시 BofA/Merrill Buy
2019-05-23 재개 Goldman Neutral
2019-04-12 개시 Evercore ISI Outperform
2019-03-06 업그레이드 Evercore ISI In-line → Outperform
2019-03-05 업그레이드 Morgan Stanley Equal-Weight → Overweight
2019-01-23 개시 UBS Neutral
2018-10-01 개시 Cantor Fitzgerald Overweight
2018-08-13 재확인 Stifel Buy
2018-08-07 업그레이드 Stifel Hold → Buy
2018-05-04 재확인 Stifel Hold
2018-03-28 개시 Evercore ISI In-line
모두보기

Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스

pulisher
04:24 AM

Free Genetic Tests May Aid People With Rare Kidney Disease - Medscape

04:24 AM
pulisher
Aug 17, 2025

Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA - MSN

Aug 17, 2025
pulisher
Aug 17, 2025

Insider Selling Trends in Nasdaq-Listed Companies: A Cautionary Lens on Alnylam, Boston Scientific, and CSX - AInvest

Aug 17, 2025
pulisher
Aug 16, 2025

Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN

Aug 16, 2025
pulisher
Aug 15, 2025

Alnylam Pharmaceuticals Inc. Reversal Rally May Surprise Bears2025 Market Overview & Technical Buy Zone Confirmations - beatles.ru

Aug 15, 2025
pulisher
Aug 15, 2025

Alnylam Pharmaceuticals stock hits all-time high at 445.44 USD By Investing.com - Investing.com Australia

Aug 15, 2025
pulisher
Aug 15, 2025

Alnylam Pharmaceuticals stock hits all-time high at 445.44 USD - Investing.com

Aug 15, 2025
pulisher
Aug 14, 2025

Alnylam Gains 2.36% on FDA Support and Buy Rating as Top 500 Volume Strategy Yields 31.52% Return - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Alnylam Raises 2025 Revenue Guidance as Losses Widen Might Change The Case For Investing In ALNY - simplywall.st

Aug 14, 2025
pulisher
Aug 13, 2025

Alnylam’s Trading Volume Surges 38.6% to Rank 113th in Market Activity - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Promising Biotech Stocks Worth WatchingAugust 12th - MarketBeat

Aug 13, 2025
pulisher
Aug 13, 2025

Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today - 富途牛牛

Aug 13, 2025
pulisher
Aug 13, 2025

Why Alnylam Pharmaceuticals Inc. stock attracts strong analyst attention [2025 Valuation Update]Low Risk Entry Point Tips - sisaissue.com

Aug 13, 2025
pulisher
Aug 12, 2025

Alnylam’s $650M Volume Ranks 168th as Shares Drop 1.17% Pre-ESC Data Presentation - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Alnylam at Canaccord Genuity: Strategic Growth and Innovation By Investing.com - Investing.com Nigeria

Aug 12, 2025
pulisher
Aug 12, 2025

Alnylam at Canaccord Genuity: Strategic Growth and Innovation - Investing.com

Aug 12, 2025
pulisher
Aug 12, 2025

Alnylam’s Vutrisiran Study: A Potential Game-Changer for Cardiomyopathy Treatment - TipRanks

Aug 12, 2025
pulisher
Aug 12, 2025

Alnylam Pharmaceuticals at Canaccord Genuity's 45th Annual Growth Conference - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025 - BioSpace

Aug 12, 2025
pulisher
Aug 11, 2025

Profits May Be Just Around The Corner For This Strong-Buy Pharma Stock - Barchart.com

Aug 11, 2025
pulisher
Aug 11, 2025

Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock - Yahoo Finance

Aug 11, 2025
pulisher
Aug 10, 2025

Alnylam Pharmaceuticals (ALNY) Is Up 9.2% After Upward Q2 Revenue Guidance Revision and Higher Analyst Forecasts—Has the Bull Case Changed? - simplywall.st

Aug 10, 2025
pulisher
Aug 10, 2025

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress - ADVFN Brasil

Aug 10, 2025
pulisher
Aug 07, 2025

Alnylam Gains 1.63% on Surging Amvuttra Sales Hits 233rd in Market Activity - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Alnylam Pharma: Strong Commercial Performance and Promising Pipeline Drive Buy Rating - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Does Alnylam’s (ALNY) Upbeat Revenue Forecast Signal Shifting Momentum in Its Long-Term Growth Story? - simplywall.st

Aug 07, 2025
pulisher
Aug 07, 2025

Vir (VIR) Q2 Revenue Drops 61% - The Motley Fool

Aug 07, 2025
pulisher
Aug 06, 2025

Alnylam Rises 2.2% on 17% Revenue Surge and Analyst Upgrades Despite 220th-Ranked 0.5B Volume Drop - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

Alnylam Pharmaceuticals stock hits all-time high at $427.0 USD - Investing.com

Aug 06, 2025
pulisher
Aug 06, 2025

Alnylam Pharmaceuticals stock hits all-time high at $427.0 USD By Investing.com - Investing.com Canada

Aug 06, 2025
pulisher
Aug 06, 2025

Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share - BioPharma Dive

Aug 06, 2025
pulisher
Aug 05, 2025

Alnylam Slips 0.15% Despite $760M Volume Ranking 137th in U.S. Equities as Mixed Pipeline Data Weigh on Momentum - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Alnylam’s Amvuttra Sales Leave Forecasts In The Dust - Finimize

Aug 05, 2025
pulisher
Aug 05, 2025

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference - Business Wire

Aug 05, 2025
pulisher
Aug 05, 2025

Alnylam Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - simplywall.st

Aug 05, 2025
pulisher
Aug 05, 2025

Analyst Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

U.S. Transthyretin Amyloidosis Treatment Market Exclusive - openPR.com

Aug 05, 2025
pulisher
Aug 04, 2025

Health Care Stocks See Gains On Strong Results And Approvals - Finimize

Aug 04, 2025
pulisher
Aug 04, 2025

Wolfe Research upgrades Alnylam Pharmaceuticals stock rating to Peerperform By Investing.com - Investing.com Canada

Aug 04, 2025
pulisher
Aug 04, 2025

Oppenheimer upgrades Alnylam stock to Outperform on strong Amvuttra sales By Investing.com - Investing.com Canada

Aug 04, 2025
pulisher
Aug 04, 2025

Earnings Estimates Rising for Alnylam (ALNY): Will It Gain? - Yahoo Finance

Aug 04, 2025
pulisher
Aug 04, 2025

Alnylam Pharmaceuticals Surges 3.79% Intraday – What’s Fueling This Sudden Rally? - AInvest

Aug 04, 2025
pulisher
Aug 04, 2025

Alnylam's Amvuttra Sales Exceeding Expectations by Sizable Margin, Oppenheimer Says - MarketScreener

Aug 04, 2025
pulisher
Aug 04, 2025

Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? - Yahoo Finance

Aug 04, 2025
pulisher
Aug 04, 2025

This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Benzinga

Aug 04, 2025
pulisher
Aug 04, 2025

Why Alnylam Pharmaceuticals (ALNY) Is Up 23.7% After Raising 2025 Revenue Outlook on AMVUTTRA Growth - simplywall.st

Aug 04, 2025
pulisher
Aug 04, 2025

What are analysts’ price targets for Alnylam Pharmaceuticals Inc. in the next 12 monthsTremendous growth potential - Jammu Links News

Aug 04, 2025
pulisher
Aug 04, 2025

Needham & Company LLC Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat

Aug 04, 2025
pulisher
Aug 03, 2025

When is Alnylam Pharmaceuticals Inc. stock expected to show significant growthDiscover top stock picks for aggressive growth - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Alnylam Pharmaceuticals Inc. compare to its industry peersUnmatched market performance - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are the latest earnings results for Alnylam Pharmaceuticals Inc.Free Capital Efficiency Planning - Jammu Links News

Aug 03, 2025

Alnylam Pharmaceuticals Inc (ALNY) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Alnylam Pharmaceuticals Inc 주식 (ALNY) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Ausiello Dennis A
Director
Aug 14 '25
Sale
436.58
31,448
13,729,536
911
$580.41
price up icon 2.55%
$653.83
price up icon 0.21%
biotechnology ONC
$321.36
price up icon 3.77%
$113.52
price up icon 0.73%
$127.80
price up icon 0.04%
자본화:     |  볼륨(24시간):